Benign prostatic hyperplasia, from pathophysiology to treatment

被引：0

作者：

Coudert, Pascal ^{[1
]}

机构：

[1] Univ Clermont Auvergne, Fac Pharm, Lab Chim Therapeut, 28 Pl Henri Dunant, F-63001 Clermont Ferrand, France

来源：

ACTUALITES PHARMACEUTIQUES | 2024年 / 63卷 / 640期

关键词：

5-alpha reductase inhibitor; alpha-blocker; benign prostatic hyperplasia; phosphodiesterase; 5; inhibitor; Serenoa repens; URINARY-TRACT SYMPTOMS;

D O I：

10.1016/j.actpha.2024.09.008

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Benign prostatic hyperplasia is the result of a number of factors. The resulting symptoms of the lower urinary tract can be improved by several classes of medication (phytotherapy, alpha-blockers, 5-alpha reductase and phosphodiesterase type5 inhibitors) or justify non-medicinal management, including surgical treatment. The therapeutic solution implemented requires support and regular monitoring to ensure patient compliance. (c) 2024 Elsevier Masson SAS.All rights reserved, including those fortext and data mining, AI training, and similartechnologies.

引用

页码：28 / 32

页数：5

共 10 条

[1]

Bardin L, 2023, PROG UROL-FMC, V33, pF38, DOI [10.1016/j.fpurol.2023.03.001, 10.1016/j.fpurol.2023.03.001, DOI 10.1016/J.FPUROL.2023.03.001]

[2] Effect of Tadalafil on Male Lower Urinary Tract Symptoms: An Integrated Analysis of Storage and Voiding International Prostate Symptom Subscores from Four Randomised Controlled Trials [J].

Chapple, Christopher R. ;

Roehrborn, Claus G. ;

McVary, Kevin ;

Ilo, Dapo ;

Henneges, Carsten ;

Viktrup, Lars .

EUROPEAN UROLOGY, 2015, 67 (01) :114-122

[3]

Delongchamps NB, Chapitre 10 Item 123 UE 5-Hypertrophie benigne de la prostate

[4]

Fougere E, 2023, Actual Pharm, V62, P16

[5] Management of benign prostatic hyperplasia [J].

Malbos, Damien .

ACTUALITES PHARMACEUTIQUES, 2022, 61 (618) :50-54

[6]

Ng M, 2024, Benign prostatic hyperplasia

[7] Lower urinary tract symptoms related to benign prostatic hyperplasia and erectile dysfunction: A systematic review [J].

Peyronnet, Benoit ;

Seisen, Thomas ;

Phe, Veronique ;

Misrai, Vincent ;

de la Taille, Alexandre ;

Roupret, Morgan .

PRESSE MEDICALE, 2017, 46 (02) :145-153

[8]

Phua Teow J, 2021, Medicines (Basel), V8, DOI [10.3390/medicines8060030, 10.3390/medicines8060030]

[9]

Sypre D, 2022, La Presse Médicale Formation, V3, P383, DOI 10.1016/j.lpmfor.2022.10.014

[10] Reliability and validity of assessment methods available in primary care for bladder outlet obstruction and benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review [J].

Vredeveld, Tom ;

van Benten, Esther ;

Beekmans, Rikie E. P. M. ;

Koops, M. Patrick ;

Ket, Johannes C. F. ;

Mollema, Jurgen ;

Ramaekers, Stephan P. J. ;

Pool, Jan J. M. ;

Coppieters, Michel W. ;

Pool-Goudzwaard, Annelies L. .

BMJ OPEN, 2022, 12 (04)

← 1 →